UAE’s Aster, Novartis sign MoU to advance digital transformation, clinical research

UAE-based Aster DM Healthcare has signed a Memorandum of Understanding (MoU) with Novartis, the global medicines company.

The MoU will enable Aster to access Novartis’ advanced therapy platforms and data science to further strengthen treatment outcomes for patients in the UAE and beyond, a statement said.

The collaboration focused on digital transformation and clinical research will aim to identify current gaps in patient care and introduce extensive medical programmes using innovative data platforms and data syndicated designs. This is in alignment with Aster’s long-term plan to integrate clinical research and digital transformation into its operations in UAE and beyond which will have a significant impact on the clinical outcome delivery for patients,

As a part of the collaboration, Novartis will enable data generation, ideation, and impactful decision making for Aster DM Healthcare’s clinical research programme. The organisations have plans to initiate a series of workshops, trainings, and educational activities, which will assist Aster to commence its activities on clinical research.

The digital transformation initiatives will also separately work on boosting the digital healthcare strategy of Aster for its market in the UAE and beyond, whereas Novartis will provide its expertise and share best practices.

“Data Analytics with focus on clinical research is one of the cornerstones of healthcare in future. Aster tries to stay ahead of the curve in offering the best medical solutions to our patients and equip our doctors with the most advanced systems to be able to do so. We have associated with Novartis in the past and are glad to enter into a multi-faceted partnership to enhance digital transformation and research,” said Dr Azad Moopen, founder chairman and managing director, Aster DM Healthcare.

“We truly believe that we share a common vision, and we are confident that this partnership has the potential to add value and have an impact on patients in UAE. We are happy to collaborate with Aster to realise their vision towards data transformation and clinical research, both of which are tantalizing growth areas for the healthcare sector,” said Mohamed Ezz Eldin, president and head of Gulf Cluster, Novartis Pharmaceuticals.

Read: Power Letters 2022: Alisha Moopen, deputy managing director, Aster DM Healthcare